CXCR3

CXCR3 Informations sur la molécule

Nom anglais	C-X-C motif chemokine receptor 3	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	2	Alias de la cible	CKR-L2，G protein-coupled receptor 9，IP-10 receptor，CXCR-3，CXC-R3，CXCR3，C-X-C Motif Chemokine Receptor 3，Interferon-Inducible Protein 10 Receptor，GPR9，C-X-C Chemokine Receptor Type 3，Chemokine Receptor 3，CD183 Antigen，CMKAR3，Chemokine (C-X-C Motif) Receptor 3，Mig Receptor，IP10-R，CD182，CD183，Mig-R，MigR，Receptors， CXCR3
Phase de R&D la plus avancée	Phase 1 Clinical

Nom anglais	C-X-C motif chemokine receptor 3
Alias de la cible	CKR-L2，G protein-coupled receptor 9，IP-10 receptor，CXCR-3，CXC-R3，CXCR3，C-X-C Motif Chemokine Receptor 3，Interferon-Inducible Protein 10 Receptor，GPR9，C-X-C Chemokine Receptor Type 3，Chemokine Receptor 3，CD183 Antigen，CMKAR3，Chemokine (C-X-C Motif) Receptor 3，Mig Receptor，IP10-R，CD182，CD183，Mig-R，MigR，Receptors， CXCR3
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	2
Phase de R&D la plus avancée	Phase 1 Clinical

CXCR3 Liste de produits

Attribut
Protein (4)Cell (2)
Bibliothèque de produits
En ligne (6)
Espèces
Human (5)Mouse (1)
Étiquette
- (5)His Tag & Flag Tag (1)
Marqueur
Unconjugated (3)- (2)Biotin-labeled (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT AI Compatible CX3-H52D5	Human	HEK293	Human CXCR3 Protein, Flag,His Tag (Detergent)	Ajouter au panier
CCHO-ATP252	Human	CHO	CHO/Human CXCR3 Stable Cell Line	Ajouter au panier
AI Compatible CHEK-ATP253	Human	HEK293	HEK293/Human CXCR3 Stable Cell Line	Ajouter au panier
AI Compatible CX3-H52P4	Human	HEK293	Human CXCR3 Full Length Protein (VLP)	Ajouter au panier
AI Compatible CX3-H82P3	Human	HEK293	Biotinylated Human CXCR3 Full Length Protein (VLP)	Ajouter au panier
AI Compatible CX3-M52P7	Mouse	HEK293	Mouse CXCR3 Full Length Protein (VLP)	Ajouter au panier

Quantité totale6

CXCR3Contexte de la molécule

Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis). Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control.

CXCR3Alias de la molécule

CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
OCU-110	OCU-10-C-110; OGX-110; OCU-110	Phase 1 Clinical	Ocugenix Corp	Macular Degeneration	Details
ACT-777991	ACT-777991	Phase 1 Clinical	Idorsia Pharmaceuticals Ltd	Diabetes Mellitus, Type 1; Inflammation	Details